IONS Stock Recent News
IONS LATEST HEADLINES
CARLSBAD, Calif. , July 5, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in a fireside chat at TD Cowen's 2nd Annual RNA Therapeutics Summit on Monday, July 10, 2023.
Data from a mid-stage study shows that treatment with Ionis' (IONS) donidalorsen over a two-year period resulted in consistent and sustained protection from HAE attacks.
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?
CARLSBAD, Calif. , May 9, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: RBC Capital Markets Global Healthcare Conference on Tuesday, May 16, 2023 Goldman Sachs 44th Annual Global Healthcare Conference on Monday, June 12, 2023 A live webcast of the presentations can be accessed on the Investors & Media section of the Ionis website at www.ionispharma.com.
Ionis (IONS) reports a narrower-than-expected Q1 loss. Sales come in line with estimates.
Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.87 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to loss of $0.46 per share a year ago.
In a high-interest-rate environment, cash is king. All biotech companies will need to continue spending to finance their R&D.
Webcast scheduled for Wednesday, May 3 at 11:30 a.m. Eastern Time CARLSBAD, Calif.
CARLSBAD, Calif. , March 28, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced its participation in fireside chats at the following investor conferences: Guggenheim Virtual Genomic Medicines and Rare Disease Days on Tuesday, April 4, 2023 22nd Annual Needham Virtual Healthcare Conference on Monday, April 17, 2023 A live webcast of the presentations can be accessed on the Investors & Media section of the Ionis website at www.ionispharma.com.
Ionis (IONS) reports positive long-term phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).